Ranbaxy Pharmaceuticals Inc, a wholly-owned subsidiary of Indian based Ranbaxy Laboratories Limited, has started distributing DisperMox (amoxicillin tablets for oral suspension in 200 mg and 400 mg strengths) in the United States.

Ranbaxy claimed it is the first to have developed a dispersible tablet form of amoxicillin that is used as an alternative to oral suspensions and offers dosing convenience and accuracy.

The DisperMox tablet immediately disperses when mixed in water and is administered in suspension form.

"As the fastest growing pharmaceutical company in the US over last five years, the launch of DisperMox is another important and exciting step in Ranbaxy's evolution into the branded pharmaceutical space," said Jeffrey Thomas, vice president, Brand Marketing and Sales.

"With the height of the respiratory season right around the corner, we think doctors and patients will find this revolutionary form of amoxicillin more convenient to administer while providing for dosing accuracy and potency."

Earlier, the Office of Generic Drugs had determined that the Ranbaxy formulation can be expected to have the same therapeutic effect as Amoxil (amoxicillin for oral suspension), which the agency referred to as the basis of safety and effectiveness.

The company will be competing in the antibiotic market with a focus on the amoxicillin suspensions market estimated to be in excess of $105.7 million in the US.